Among them, BCL-2, whose involvement in CLL has already been extensively described [48] and whose therapeutic targeting with mimetic compounds has already shown to be efficient for some CLL patients [49, 50]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.